Patient Preferences for Lung Cancer Interception Therapy
Value in Health
; 26(6 Supplement):S343, 2023.
Article
Dans Anglais
| EMBASE | ID: covidwho-20237334
ABSTRACT
Objectives:
Interception therapy requires an individual to take a treatment today to prevent a future medical event. Patients must trade off treatment burdens incurred today against future benefits. We examined the preferences of high-risk lung cancer (LC) individuals for potential interception therapies that reduce the risk of developing lung cancer. Method(s) An online discrete-choice experiment (DCE) was developed for hypothetical LC interception treatments with four attributes reduction in risk of LC over 3 years, injection site reaction severity, nonfatal serious infection risk, and death from serious infection risk. Respondents chose between two alternative treatments or a no-treatment option. The DCE was analyzed using random-parameters logit, and maximum acceptable risk for an LC risk reduction was calculated. Logit analysis explored characteristics of respondents who always selected no treatment. Result(s) The sample included 803 adults aged 50-80 years with at least a 20 pack-year smoking history. Respondents had an average willingness to accept interception therapy (alternative-specific constant=1.30, 95% CI 0.91-1.69). Respondents viewed larger reductions in the risk of LC as most important. Respondents were willing to accept increases in risk of nonfatal serious infection up to 15% for a 15% improvement in relative LC risk reduction and increases in risk of death from serious infection up to 1.5% for a 23% improvement in relative LC risk reduction. However, 16% of respondents selected 'no treatment' for all DCE questions. Older respondents, current smokers who have never tried to quit, and those who did not get regular skin exams for cancer and/or COVID-19 vaccine were more likely to opt out of interception therapy. Conclusion(s) Generally, individuals at high risk of LC are willing to consider interception therapy. Study results can support benefit-risk assessments for future systemic LC interception treatments, and the results may have implications for other therapeutic areas.Copyright © 2023
adult; aged; cancer patient; cancer risk; conference abstract; controlled study; coronavirus disease 2019; current smoker; female; human; human tissue; infection risk; injection site reaction; lung cancer; major clinical study; male; middle aged; mortality; patient preference; risk assessment; risk reduction; skin; smoking; SARS-CoV-2 vaccine
Texte intégral:
Disponible
Collection:
Bases de données des oragnisations internationales
Base de données:
EMBASE
Type d'étude:
Étude pronostique
/
Essai contrôlé randomisé
Les sujets:
Vaccins
langue:
Anglais
Revue:
Value in Health
Année:
2023
Type de document:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS